Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Non-Current Liabilities (2019 - 2024)

Lipocine's Total Non-Current Liabilities history spans 8 years, with the latest figure at $1.6 million for Q3 2024.

  • For Q3 2024, Total Non-Current Liabilities fell 29.61% year-over-year to $1.6 million; the TTM value through Sep 2024 reached $1.6 million, down 29.61%, while the annual FY2023 figure was $2.6 million, 55.8% up from the prior year.
  • Total Non-Current Liabilities reached $1.6 million in Q3 2024 per LPCN's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $10.3 million in Q2 2021 to a low of -$35.5 million in Q2 2022.
  • Average Total Non-Current Liabilities over 5 years is -$888573.2, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: surged 211.0% in 2021, then plummeted 443.94% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at -$10.0 million in 2020, then skyrocketed by 161.11% to $6.1 million in 2021, then crashed by 72.56% to $1.7 million in 2022, then surged by 55.8% to $2.6 million in 2023, then crashed by 39.66% to $1.6 million in 2024.
  • Per Business Quant, the three most recent readings for LPCN's Total Non-Current Liabilities are $1.6 million (Q3 2024), $1.7 million (Q2 2024), and $1.4 million (Q1 2024).